Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to ...

7 Memoirs You Should Read If You Desperately Need Motivation

Feeling stuck or uninspired? These seven powerful memoirs will remind you how ordinary lives can become extraordinary through courage and self-discovery, Books, Times Now ...